Pyoderma gangrenosum
Pyoderma gangrenosum nexweşiyek çermî ya nadir, înflamatuar e ku pûstûl an girêkên bi êş dibin ulcerên ku bi pêşdeçûn mezin dibin. Pyoderma gangrenosum ne enfeksiyonê ye. Dibe ku dermankirin kortîkosteroîd, ciklosporîn, an antîpên monoklona yên cihêreng bin. Her çend ew dikare bandorê li mirovên her temenî bike jî, ew bi piranî li mirovên 40 û 50 salî bandor dike.
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Li ser lingê kesê bi kolîta ulceratîf.
References
Pyoderma gangrenosum rewşek çermî ya kêm e ku dibe sedema ulcerên bi êş ên bi keviyên sor an morî. Ew wekî nexweşiyek înflamatuar tê dabeş kirin û beşek ji komeke bi navê dermatozên neutrofîlî ye. Sedema pyoderma gangrenosum tevlihev e, di nav mirovên ku ji hêla genetîkî ve meyla wan in de pirsgirêkên hem bi berevaniya xwezayî û hem jî bi adapteyî re têkildar e. Di van demên dawî de, lêkolîner balê dikişînin ser pelika porê wekî xalek destpêka nexweşiyê.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum rewşek çermî ya hindik e ku dibe sedema ulcerên pir bi êş. Dema ku em bi tevahî sedema wê fam nakin, em dizanin ku ew çalakiya hin hucreyên berevaniyê zêde dike. Dermankirina nexweşiyê hîn jî ne hêsan e. Dermanên me yên cihêreng hene ku pergala berevaniyê ditepisînin an çalakiya wê diguhezînin. Li gel van, em li ser dermankirina birînan û birêvebirina êşan jî disekinin. Corticosteroids û cyclosporine bi gelemperî ji bo dermankirinê bijareya yekem in, lê di van demên dawî de, li ser karanîna dermanên biyolojîk ên mîna frendêrên TNF-α bêtir lêkolîn hene. Van biyolojîkî her ku diçe bêtir têne tercîh kirin, nemaze di nexweşên bi şert û mercên înflamatuar ên din de, û ew di pêvajoya nexweşiyê de berê têne bikar anîn.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
